Status:
COMPLETED
The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis
Lead Sponsor:
Phramongkutklao College of Medicine and Hospital
Collaborating Sponsors:
Silpakorn University
Conditions:
Seizures
Eligibility:
All Genders
18+ years
Brief Summary
Levetiracetam (LEV) is one of second-generation antiepileptic drugs that has been used to treat partial and generalized epilepsy. LEV is eliminated from the systemic circulation by renal excretion. Th...
Eligibility Criteria
Inclusion
- Patients who were at least 18 years old.
- Patients who were diagnosed with seizure.
- Patients who were undergoing intermittent hemodialysis and were treated with intravenous Levetiracetam not less than 2 days
Exclusion
- Patients who were pregnant or lactating
- Patients who were treated with intravenous Levetiracetam more than once a day
- Patients who were undergoing sustained low efficiency dialysis (SLED)
- Patients who have intermittent dialysis duration less than 3 hours
Key Trial Info
Start Date :
November 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 10 2019
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04511676
Start Date
November 1 2018
End Date
October 10 2019
Last Update
August 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmongkutklao Hospital
Ratchathewi, Bangkok, Thailand, 10400